ClinicalTrials.gg
Active, not recruitingNCT05338970Updated Aug 27, 2026

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

A Phase 3 interventional study of Patritumab Deruxtecan and Platinum-based chemotherapy in Nonsquamous Non-small Cell Lung Cancer, EGFR L858R and EGFR Exon 19 Deletion, sponsored by Daiichi Sankyo. Active, not recruiting at 182 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
586
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo — 5 open to participants now, 16 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Daiichi Sankyo.

Enrollment
8th of 31
586 · median 181
Started
2022
with 2 others
Phase 3
8 of 41
1 open now
Primary completion
2024-05
later than 2 of 15 live
Registered
28th of 41
by date

Among the 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo, this one is the 8th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2022, is one of 8 in phase 3, reaches primary completion later than 2 of the 15 other live ones, and was the 28th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo, or all of them as a file.
02

Study summary

Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile. There is an urgent need for more effective and tolerable therapies for patients with EGFRm NSCLC who have exhausted available targeted therapies. Clinical evidence suggests that patritumab deruxtecan constitutes a promising investigational therapy for patients with EGFRm NSCLC.

Read the detailed description

Patritumab deruxtecan (HER3-DXd, U3-1402) is an antibody-drug conjugate (ADC) comprising an anti-HER3 mAb linked to a topoisomerase I inhibitor that is in clinical development for patients with NSCLC, metastatic breast cancer, and colorectal cancer.

The primary objective of the current study is to compare the efficacy of patritumab deruxtecan versus platinum-based chemotherapy, as measured by progression-free survival (PFS) and the key secondary endpoint of overall survival (OS), in participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation (exon 19 deletion or L858R) after failure of third-generation (eg, osimertinib, lazertinib, aumolertinib, alflutinib) EGFR TKI therapy.

03

Conditions studied

  • Nonsquamous Non-small Cell Lung Cancer
  • EGFR L858R
  • EGFR Exon 19 Deletion

Keywords

  • Nonsquamous Non-small Cell Lung Cancer
  • EGFR L858R
  • EGFR exon 19 deletion
  • Patritumab deruxtecan
  • HER3-DXd
  • U3-1402
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is a male or female subject aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years old).
  2. Has or cytologically documented or locally advanced non-squamous NSCLC not amenable to curative surgery or radiation.
  3. Has documentation of an EGFR-activating mutation detected from tumor tissue or blood sample: exon 19 deletion or L858R at diagnosis or thereafter.
  4. Received 1 or 2 prior line(s) of an approved EGFR TKI treatment in the metastatic or locally advanced setting, which must include a third -generation EGFR TKI.
  5. May have received either and/or adjuvant treatment if progression to metastatic or locally advanced disease occurred at least 12 months after the last dose of such therapy and subsequently experienced disease progression on or after third-generation EGFR TKI treatment administered in the metastatic or locally advanced setting.
  6. Has not received any other prior systemic therapies in the metastatic or locally advanced setting (including chemotherapy, immunotherapy etc) (even if administered in combination with EGFR TKI).
  7. Has documentation of radiographic disease progression while receiving or after receiving a third generation EGFR TKI for metastatic or locally advanced disease.
  8. Has at least 1 as per v1.1 by Investigator assessment.
  9. Is willing to have a tumor or provide recently obtained tumor tissue.
  10. Has an performance status (ECOG PS) of 0 or 1 at Screening.
  11. Has adequate bone marrow reserve and organ function based on local laboratory evaluation within 14 days prior to randomization:

    • count: ≥100,000/mm\^3 or ≥100 × 10\^9/L within 14 days prior to the assessment of platelet count during the Screening Period
    • : ≥1500/mm\^3 or ≥1.5 × 10\^9/L within 14 days prior to the assessment of absolute neutrophil count during the Screening Period
    • (Hgb): ≥9.0 g/dL within 14 days prior to the assessment of hemoglobin during the Screening Period
    • Creatine clearance (): CrCl ≥45 mL/min calculated by using the Cockcroft-Gault equation or measured CrCl
    • (AST)/Alanine aminotransferase (ALT): AST/ALT ≤3× (ULN)
    • Total (TBL): TBL ≤1.5 × ULN
    • Serum albumin: ≥2.5 g/dL
    • (PT) or Prothrombin time-International normalized ratio (PT-INR) and activated partial thromboplastin time (aPTT)/partial thromboplastin time (PTT): ≤1.5 × ULN, except for participants receiving coumarin-derivative anticoagulants or other similar anticoagulant therapy who must have PT-INR within therapeutic range as deemed appropriate by the Investigator

Exclusion criteria

Exclusion Criteria:

  1. Has any previous histologic or cytologic evidence of small cell OR combined small cell/non-small cell disease in the or pretreatment tumor biopsy, or squamous NSCLC histology.
  2. Has any history of interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis), has current ILD, or is suspected to have such disease by imaging during Screening.
  3. Has clinically severe respiratory compromise (based on the Investigator's assessment) resulting from intercurrent pulmonary illnesses including, but not limited to the following:

    • Any underlying pulmonary disorder, restrictive lung disease, or pleural effusion
    • Any , connective tissue, or inflammatory disorders where there is documented, or a suspicion of pulmonary involvement at the time of Screening
    • OR prior complete pneumonectomy
  4. Is receiving chronic systemic dosed at >10 mg prednisone or equivalent anti-inflammatory activity or any form of therapy prior to randomization.
  5. Has any history of or evidence of current .
  6. Has evidence of clinically active spinal cord compression or , defined as being symptomatic and untreated, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.
  7. Any prior treatment with any agent including an antibody drug conjugate (ADC) containing a chemotherapeutic agent targeting topoisomerase I, human epidermal growth factor receptor 3 (HER3) antibody, and any systemic therapies (other than EGFR TKIs) in the /locally advanced setting, including chemotherapy or any other systemic therapy in combination with an EGFR TKI.
  8. Has history of other active within 3 years prior to randomization, except for adequately resected nonmelanoma skin cancer, adequately treated intraepithelial carcinoma of the cervix, and any other curatively treated in situ disease.
  9. Has uncontrolled or significant cardiovascular disease prior to randomization.
  10. Has active and/or infection, such as those with serologic evidence of active viral infection within 28 days of randomization.
  11. Has a known (HIV) infection that is not well controlled.
  12. Has corneal disease.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
586 participants (actual)

Study arms

  • Experimental
    Patritumab deruxtecan

    Participants received patritumab deruxtecan (HER3-DXd) 5.6 milligrams per kilogram (mg/kg), intravenously (IV) on Day 1 of each 21-day cycle (every 3 weeks \[q3W\]) until occurrence of unacceptable toxicity, radiographic or clinical disease progression (PD), withdrawal of consent, physician decision, pregnancy, loss to follow-up or death, whichever occurs first; data cut-off (DCO) date: 31 May 2024.

    Drug: Patritumab Deruxtecan

  • Active comparator
    Platinum-based chemotherapy

    Participants received platinum-based chemotherapy; pemetrexed (500 milligrams per square meter \[mg/m\^2\]) plus either cisplatin (75 mg/m\^2) or carboplatin (target area under the plasma concentration-time curve of 5 \[AUC5\] by using the Calvert formula), IV on Day 1 of each cycle up to 4 cycles or until PD, whichever occurs first. Participants without disease progression after 4 cycles of platinum plus pemetrexed therapy continued treatment with maintenance pemetrexed with no restriction on the number of cycles; data cut-off (DCO) date: 31 May 2024.

    Drug: Platinum-based chemotherapy

Interventions

  • Intravenous administration, 5.6 mg/kg every 3 weeks (q3W).

    Also known as: HER3-DXd, U3-1402

  • DrugPlatinum-based chemotherapy

    Intravenous, pemetrexed 500 mg/m\^2 plus either cisplatin (75 mg/m\^2) or carboplatin (target area under the plasma concentration time curve of 5 \[AUC5\] by using the Calvert formula) q3W.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Based on RECIST v1.1

    Progression-free survival (PFS) is defined as the time from the date of randomization to the earlier of the dates of the first documentation of objective progression of disease or death due to any cause.

    Time frame: Baseline up to approximately 49 months

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: Baseline up to approximately 32 months

  2. Progression-free Survival (PFS) as Assessed by Investigator Review Based on RECIST v1.1

    Progression-free survival (PFS) is defined as the time from the date of randomization to the earlier of the dates of the first documentation of objective progression of disease or death due to any cause.

    Time frame: Baseline up to approximately 49 months

  3. Progression-free Survival (PFS) as Assessed by Local Standard Clinical Practice

    Progression-free survival (PFS) by local standard clinical practice is defined as the time from date of randomization to the documented progression on the first new anticancer therapy (if administered) or death due to any cause, whichever occurred first.

    Time frame: Baseline up to approximately 49 months

  4. Objective Response Rate (ORR) as Assessed by BICR and Investigator Review Based on RECIST v1.1

    Objective response rate (ORR) is defined as the proportion of participants who have a confirmed best overall response (BOR) of complete response (CR) or partial response (PR).

    Time frame: Baseline up to approximately 49 months

  5. Duration of Response (DoR) as Assessed by BICR and Investigator Review Based on RECIST v1.1

    Duration of response (DoR) is defined as the time from the first documentation of objective response (CR or PR) to the earlier of the dates of the first documentation of objective progression of disease or death due to any cause.

    Time frame: Baseline up to approximately 49 months

  6. Clinical Benefit Rate (CBR) as Assessed by BICR and Investigator Review Based on RECIST v1.1

    Clinical benefit rate (CBR) will be assessed by BICR and Investigator based on RECIST v1.1. CBR is defined as the proportion of participants who have a confirmed BOR of CR, PR, or stable disease (SD) that lasts for at least 180 days.

    Time frame: Baseline up to approximately 49 months

  7. Disease Control Rate (DCR) as Assessed by BICR and Investigator Review Based on RECIST v1.1

    Disease control rate (DCR) is defined as the proportion of participants who have a confirmed BOR of CR, PR, or SD.

    Time frame: Baseline up to approximately 49 months

  8. Time to Response (TTR) as Assessed by BICR and Investigator Review Based on RECIST v1.1

    Time to response (TTR) is defined as the time from the date of randomization to the date of the first documentation of response (CR or PR) that is subsequently confirmed.

    Time frame: Baseline up to approximately 49 months

  9. Intracranial PFS as Assessed by BICR

    Intracranial PFS is defined as the time from the date of randomization to the earlier of the dates of the first documented radiographic intracranial disease progression or death, whichever comes first, as assessed by BICR per CNS-RECIST, in participants with CNS lesion(s) at baseline by BICR per CNS-RECIST.

    Time frame: Baseline up to approximately 49 months

  10. Mean Change from Baseline in Non-small Cell Lung Cancer - Symptom Assessment Questionnaire

    The NSCLC-SAQ will assess disease-related symptom change in patients with NSCLC.

    Time frame: Baseline up to approximately 49 months

  11. Mean Change from Baseline in Patient's Global Impression of Change

    The PGI-C is a 7-point scale depicting a participant's rating of overall improvement.

    Time frame: Baseline up to approximately 49 months

  12. Mean Change from Baseline in Patient's Global Impression of Severity

    The PGI-S is a one-item questionnaire that contains six response options.

    Time frame: Baseline up to approximately 49 months

  13. Mean Change from Baseline in Patient's Global Impression of Treatment Tolerability

    The PGI-TT will capture the patient's overall impression of treatment tolerability.

    Time frame: Baseline up to approximately 49 months

  14. Mean Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)

    The EORTC-QLQ-C30 will assess the patient's overall quality of life (QoL).

    Time frame: Baseline up to approximately 49 months

  15. Mean Change from Baseline in EuroQol Questionnaire-5 dimensions-5 levels (EQ-5D-5L)

    The EQ-5D-5L is a standardized instrument that will be used for measuring generic health status required for health technology assessments.

    Time frame: Baseline up to approximately 49 months

  16. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs will be graded by using National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.

    Time frame: Baseline up to approximately 49 months

  17. Percentage of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline)

    The immunogenicity of patritumab deruxtecan will be confirmed by assessing the anti-drug antibodies.

    Time frame: Baseline up to approximately 49 months

  18. Percentage of Participants Who Have Treatment-emergent ADA

    The immunogenicity of patritumab deruxtecan will be confirmed by assessing the anti-drug antibodies.

    Time frame: Baseline up to approximately 49 months

07

Study locations

182 sites

Showing the first 100 of 182 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Mok T, Janne PA, Nishio M, Novello S, Reck M, Steuer C, Wu YL, Fougeray R, Fan PD, Meng J, Sternberg DW, Esker S, Yu HA. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI. Future Oncol. 2024 May;20(15):969-980. doi: 10.2217/fon-2023-0602. Epub 2023 Dec 14. PubMed 38095056 ↗
  • Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, Yoh K, Lee SH, Paz-Ares L, Besse B, Bironzo P, Kim DW, Johnson ML, Wu YL, John T, Kao S, Kozuki T, Massarelli E, Patel J, Smit E, Reckamp KL, Dong Q, Shrestha P, Fan PD, Patel P, Sporchia A, Sternberg DW, Sellami D, Janne PA. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. J Clin Oncol. 2023 Dec 10;41(35):5363-5375. doi: 10.1200/JCO.23.01476. Epub 2023 Sep 10. PubMed 37689979 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in May 2024, 22 months.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 22 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2022
First posted
Apr 21, 2022
StartActual
Jul 8, 2022
Primary completionActual
May 31, 2024
CompletionEst.
Dec 31, 2026
Results delay requested
Jan 13, 2025
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05338970
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Apr 21, 2022
Start date
Jul 8, 2022
Primary completion
May 31, 2024
Completion
Dec 31, 2026 (estimated)
Last update
Aug 27, 2026

Study contacts

Physician Scientist
study director · Daiichi Sankyo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Patritumab deruxtecan

Start the discussion